This Insider Has Just Sold Shares In Akeso
This Insider Has Just Sold Shares In Akeso
Some Akeso, Inc. (HKG:9926) shareholders may be a little concerned to see that the Co-Founder, Baiyong Li, recently sold a substantial HK$214m worth of stock at a price of HK$71.48 per share. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 5.6%.
一些康方生物(HKG:9926)的股東可能會對公司創始人李白勇最近以每股71.48港元的價格出售價值21400萬港元的股票感到有些擔憂。然而,重要的是要注意到他們仍然大力投資於該股票,這次出售僅減少了他們的持股5.6%。
Akeso Insider Transactions Over The Last Year
過去一年康方生物內部交易
In fact, the recent sale by Baiyong Li was the biggest sale of Akeso shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at around the current price of HK$65.45. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
實際上,根據我們的記錄,李白勇最近的出售是康方生物在過去十二個月內由內幕人士進行的最大股票出售。這意味着一名內幕人士在當前價格65.45港元左右出售了股票。雖然我們通常不喜歡看到內幕拋售,但如果拋售是在更低價格進行那就更令人擔憂。我們注意到這次出售是在當前價格附近進行的,因此並不是主要擔憂,儘管這也不是一個好兆頭。
In the last year Akeso insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去的一年裏,康方生物的內幕人士沒有購買任何公司股票。下圖顯示了過去一年內內幕交易(由公司和個人進行)的情況。如果您點擊圖表,您可以查看所有個別交易,包括股價、個人和日期!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人,可以免費查看最新內部交易股票的小盤公司名單,這可能正是您要找的機會。
Insider Ownership Of Akeso
康方生物的內部持股情況
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Akeso insiders own 20% of the company, worth about HK$12b. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
對於普通股東來說,了解公司內部人士持有多少股份是很重要的。 通常,內部持股越高,內部人士越有可能被激勵長期建設公司。 很高興看到康方生物的內部人士持有公司20%的股份,價值約120億港元。 我喜歡看到這種內部持股水平,因爲這增加了管理層考慮股東最佳利益的可能性。
What Might The Insider Transactions At Akeso Tell Us?
康方生物的內幕交易可能告訴我們什麼?
Insiders sold Akeso shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Akeso.
內部人士最近賣出了康方生物的股票,但沒有買入過。 即使我們看去年,我們也沒有看到任何購買。 高內部持股是好的,但內部人士的出售讓我們感到謹慎。 所以這些內幕交易可以幫助我們形成對股票的看法,但了解這家公司面臨的風險也是非常重要的。 爲了幫助您,我們發現了一個警告信號,您應該關注以便更好地了解康方生物。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。